Drug Benefit Managers Call Feds' Price Disclosure Rule Faulty
The trade group for businesses that negotiate drug prices for health insurers has stepped up its fight over Trump-era price transparency rules, urging a D.C. federal judge to nix the mandates...To view the full article, register now.
Already a subscriber? Click here to view full article